LunaRx vs. Ro: GLP-1 Telehealth Compared
Pricing, formulations, and clinical approach — how LunaRx differs from Ro's GLP-1 program.

Disclosure
The GLP Journal is published by LunaRx, so this comparison is written with that conflict disclosed. We aim for accuracy, not advocacy. Compounded GLP-1s are prepared by licensed 503A and 503B compounding pharmacies. This is not medical advice.
LunaRx and Ro both deliver GLP-1 weight care through telehealth, but they are built on different premises. Ro is a large all-in-one platform that bundles many services under one account; LunaRx is a focused, physician-directed program built around a single outcome — losing fat while protecting muscle, with a structured plan to come off. Here is the honest side-by-side.
Both connect you with a licensed provider and, if appropriate, a compounded GLP-1 from a licensed pharmacy. The real differences are in the care model, what is included in the protocol, how transparent the pricing is, and whether there is a plan for the end.
| LunaRx | Ro | |
|---|---|---|
| Focus | Recomposition — lose fat, keep muscle | All-in-one platform, weight included |
| Care model | Physician-directed, plan calibrated to you | Platform-led, bundled services |
| Medications | Semaglutide or tirzepatide | GLP-1 options vary by state and availability |
| Muscle protection | Muscle-protective peptides built into the stack | Not a stated focus |
| Coming-off plan | Structured off-ramp / taper, central to the model | Not emphasized |
| Pricing | Flat, dose-independent — $139/mo semaglutide, $149/mo tirzepatide | Bundled monthly; per-item cost can be opaque |
| If not approved | $0 — you only pay if a physician approves | Check current policy |
| Languages | English and Spanish, intake to taper | Primarily English |
| Supply | Compounded, via licensed 503A and 503B pharmacies | Compounded and/or brand, varies |
How the care models differ
Ro is built as a broad platform — a single account that spans multiple conditions and services, with weight care as one offering among many. That breadth is convenient if you want several things in one place. LunaRx does one thing: metabolic recomposition. A licensed physician reviews your intake and calibrates a plan to you, and the same clinical thread runs from your first assessment through your taper.
The trade is breadth versus depth. A platform gives you range; a focused program gives you a plan built around a single goal and titrated to your physiology.
What is actually in the protocol
A standard GLP-1 program prescribes the medication and titrates the dose. LunaRx pairs the GLP-1 with muscle-protective peptides and recovery support, because a real share of the weight lost on a GLP-1 alone can be lean muscle. The aim is that what you lose is fat and what stays is strength — recomposition, not just a smaller number.
Pricing: read the bundle carefully
LunaRx uses flat, dose-independent pricing — $139/month for semaglutide and $149/month for tirzepatide as of 2026 — so your cost does not climb as you titrate up. Bundled platform pricing can be harder to parse: it is worth separating the medication cost from membership or add-on fees so you know the real per-item total. Compare the all-in monthly cost at your expected dose, and confirm current pricing on each service's own page.
The coming-off question
Most platforms are built around the ongoing refill. LunaRx is built around the exit: a structured taper paired with GI-recovery and metabolic-reset support, so you can come off without the rebound that tends to follow an abrupt stop. If the end game matters to you, it is central to the LunaRx model rather than an afterthought.
Where Ro may fit better
If you want a single platform for several health needs and value having everything under one account, Ro's breadth is a genuine advantage. Just separate the medication cost from bundle fees and confirm exactly what GLP-1 product you would receive before deciding.
Who LunaRx is for
- You want to keep your muscle, not just lose weight.
- You want a physician-directed plan calibrated to you.
- You want a real plan to come off — a taper, not an open-ended subscription.
- You want flat, transparent pricing with no bundle to decode.
- You want care in English or Spanish.
Want this handled for you?
LunaRx — clinician-led GLP-1 care with a plan to come off
LunaRx connects you with a licensed clinician for an online evaluation. Depending on your state that is a live or a store-and-forward visit. If the clinician determines a GLP-1 is appropriate for you, a licensed pharmacy dispenses it — with a plan to come off when you’re ready. The prescribing decision is the clinician’s alone, and approval is not guaranteed.
What to verify with LunaRx and Ro
- Is this a compounded or a branded product? If compounded, which licensed 503A or 503B pharmacy prepares it, and is it properly licensed? Compounding compliance rests with the dispensing pharmacy.
- The total monthly cost — bundled pricing can hide the real per-item cost.
- Whether muscle-protective support is included or extra.
- What happens to your plan and price if you stop.
Common questions about LunaRx vs Ro
- What is the main difference between LunaRx and Ro?
- LunaRx is a focused, physician-directed recomposition program — a GLP-1 paired with muscle-protective peptides and a structured off-ramp. Ro is a broad all-in-one telehealth platform bundling many services, where per-item pricing can be less transparent.
- Which is cheaper, LunaRx or Ro?
- It depends on your dose and what is bundled. LunaRx uses flat pricing — $139/month for semaglutide and $149/month for tirzepatide as of 2026 — that does not rise as you titrate up. With a bundled platform, separate the medication cost from membership or add-on fees, then compare the all-in monthly total.
- Do LunaRx and Ro sell compounded GLP-1s?
- LunaRx dispenses compounded GLP-1s via licensed 503A and 503B compounding pharmacies. Ro offers compounded and/or brand depending on the state. Confirm which product you would receive and which licensed pharmacy fills it.
- Does either help you keep muscle?
- LunaRx builds muscle-protective peptides into the protocol to reduce lean-mass loss during weight loss. A standard GLP-1 program typically prescribes the medication alone, so ask whether muscle support is included.
- Does either help you come off the medication?
- LunaRx makes a structured taper central to the model. Coming-off support is not a stated emphasis of most platforms, so ask what the plan is for the end.
- How do I get started with LunaRx?
- Complete a short online eligibility check in English or Spanish. A licensed physician reviews it and approves or denies treatment. You are only charged if you are approved.
Bottom line
Ro is a broad, bundled platform; LunaRx is a focused, physician-directed recomposition program with muscle-protective peptides, flat pricing, and a built-in off-ramp. If you want many services under one account, Ro fits. If you want to lose fat, keep muscle, and come off on a plan, that is what LunaRx is built for. We disclose that we publish this comparison — verify pricing and fit for your situation.
Sources
Primary sources for the claims in this article. Trial results are reported as published; prescribing information is the authoritative reference for dosing and safety.
- 1.FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
U.S. Food and Drug Administration · 2025
Shortages resolved (tirzepatide December 2024, semaglutide February 2025) and the compounding enforcement deadlines that followed.
- 2.Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A
U.S. Food and Drug Administration, guidance for industry · 2018
A 503A pharmacy may not compound, regularly or in inordinate amounts, a drug that is essentially a copy of a commercially available product. Patient-specific compounding remains possible where the prescriber documents a clinically significant difference for that patient.
- 3.FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
U.S. Food and Drug Administration · 2026
April 2026 proposal to exclude these molecules from the 503B bulk drug substances list.
Get the weekly research update
New trials, FDA moves, and pricing shifts — one plain-English email a week. No spam.
Unsubscribe anytime. Read our privacy policy.
Related in Comparisons

Comparisons
Semaglutide vs. Tirzepatide: What the Head-to-Head Trial Showed
7 min read · Updated Oct 10, 2026

Comparisons
Wegovy Pill vs. Injection: How the Oral and Weekly Versions Compare
9 min read · Updated Oct 28, 2026

Comparisons
LunaRx vs. Hims: GLP-1 Telehealth Compared
9 min read · Updated Oct 5, 2026